Literature DB >> 11718431

Chronic myelogenous leukemia: the news you have and haven't heard.

M E Kalaycio1.   

Abstract

Chronic myelogenous leukemia (CML) can usually be cured by bone marrow transplantation from matched donors. Donor T-cell activity from the graft is critical to maintaining remission. Myeloablation may not be necessary for cure. Non-myeloablative but immunosuppressive preparative regimens allow donor engraftment with less toxicity. Early combination therapy with interferon-alfa and cytarabine was the preferred option for patients who could not undergo bone marrow transplantation. Now, the advent of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, promises to change existing treatment paradigms

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718431     DOI: 10.3949/ccjm.68.11.913

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  3 in total

1.  Chronic myeloid leukemia presenting with visual and auditory impairment in an adolescent: an insight to management strategies.

Authors:  Muge Gokce; Sule Unal; Benan Bayrakçı; Murat Tuncer
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-01       Impact factor: 0.900

Review 2.  Therapy of chronic myeloid leukemia: twilight of the imatinib era?

Authors:  Ewelina Trela; Sylwester Glowacki; Janusz Błasiak
Journal:  ISRN Oncol       Date:  2014-01-30

Review 3.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.